Bystolic Advisory Committee: Trial Shortcomings Could Mean Tough Panel Review

Single pivotal trail for Forest's beta blocker may produce a skeptical audience on Jan. 11, when an FDA advisory committee evaluates the additional requested indication for chronic heart failure.